NovaBay Pharma (NYSE:NBY)‘s stock had its “hold” rating reiterated by equities researchers at Maxim Group in a report released on Tuesday.

Shares of NovaBay Pharma (NYSE:NBY) traded up 2.49% during mid-day trading on Tuesday, reaching $3.70. The company had a trading volume of 23,557 shares. The firm has a 50-day moving average price of $3.23 and a 200-day moving average price of $2.59. NovaBay Pharma has a 1-year low of $1.75 and a 1-year high of $9.50. The stock’s market capitalization is $41.63 million.

NovaBay Pharma (NYSE:NBY) last issued its earnings results on Thursday, August 11th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by $0.06. The company earned $2.70 million during the quarter, compared to the consensus estimate of $1.76 million. Equities analysts expect that NovaBay Pharma will post ($1.77) earnings per share for the current year.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/novabay-pharma-nby-given-hold-rating-at-maxim-group.html

About NovaBay Pharma

NovaBay Pharmaceuticals, Inc, formerly NovaCal Pharmaceuticals, Inc, is a biopharmaceutical company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox.

5 Day Chart for NYSE:NBY

Receive News & Ratings for NovaBay Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharma and related companies with MarketBeat.com's FREE daily email newsletter.